Information:
Fel:
ID
34147
Beskrivning
A Combined GWAS and miRNA for the Identification of Bevacizumab Response Predictors in Metastatic Breast Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT01598285
Länk
https://clinicaltrials.gov/show/NCT01598285
Nyckelord
Versioner (1)
- 2019-01-14 2019-01-14 -
Rättsinnehavare
GSK group of companies
Uppladdad den
14 januari 2019
DOI
För en begäran logga in.
Licens
Creative Commons BY-NC 3.0
Modellkommentarer :
Här kan du kommentera modellen. Med hjälp av pratbubblor i Item-grupperna och Item kan du lägga in specifika kommentarer.
Itemgroup-kommentar för :
Item-kommentar för :
Du måste vara inloggad för att kunna ladda ner formulär. Var vänlig logga in eller registrera dig utan kostnad.
Eligibility Breast Cancer Invasive Nos NCT01598285
Eligibility Breast Cancer Invasive Nos NCT01598285
- StudyEvent: Eligibility
Similar models
Eligibility Breast Cancer Invasive Nos NCT01598285
- StudyEvent: Eligibility
Name
Typ
Description | Question | Decode (Coded Value)
Datatyp
Alias
ID.1
Item
patients with breast cancer, at a disseminated stage
boolean
ID.2
Item
patients treated with bevacizumab in combination with weekly paclitaxel as first line chemotherapy and who have progressed
boolean
ID.3
Item
alive patients authorizing the extraction and analysis of their biological samples.
boolean
ID.4
Item
patients with a second neoplasia
boolean
ID.5
Item
deceased patients
boolean
ID.6
Item
patients who have not agreed to participate in the study
boolean
ID.7
Item
her2 positive patients
boolean
ID.8
Item
patients with cns metastases when first treated with bevacizumab in combination with paclitaxel
boolean
ID.9
Item
patients with local-regional recurrence only and
boolean
ID.10
Item
patients with status ned (resected metastases)
boolean